Drug Type Small molecule drug |
Synonyms Iap inhibitor at-406, SMAC mimetic, AT 406 + [5] |
Action inhibitors, inducers |
Mechanism Inhibitors of apoptosis (IAP) protein family inhibitors, XIAP inhibitors(Inhibitor of apoptosis protein 3 inhibitors), cIAP1 inhibitors(Cellular inhibitor of apoptosis protein 1 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
License Organization |
Drug Highest PhasePhase 3 |
First Approval Date- |
RegulationBreakthrough Therapy (United States) |
Molecular FormulaC32H44ClN5O4 |
InChIKeyDBXTZCYPHKJCHF-ZZPLZQMBSA-N |
CAS Registry1071992-57-8 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Squamous Cell Carcinoma of Head and Neck | Phase 3 | China | 06 Oct 2022 | |
Squamous Cell Carcinoma of Head and Neck | Phase 3 | Taiwan Province | 06 Oct 2022 | |
Head and Neck Neoplasms | Phase 3 | United States | 30 Jan 2022 | |
Locally Advanced Head and Neck Squamous Cell Carcinoma | Phase 3 | United States | 07 Aug 2020 | |
Locally Advanced Head and Neck Squamous Cell Carcinoma | Phase 3 | China | 07 Aug 2020 | |
Locally Advanced Head and Neck Squamous Cell Carcinoma | Phase 3 | Japan | 07 Aug 2020 | |
Locally Advanced Head and Neck Squamous Cell Carcinoma | Phase 3 | Argentina | 07 Aug 2020 | |
Locally Advanced Head and Neck Squamous Cell Carcinoma | Phase 3 | Australia | 07 Aug 2020 | |
Locally Advanced Head and Neck Squamous Cell Carcinoma | Phase 3 | Austria | 07 Aug 2020 | |
Locally Advanced Head and Neck Squamous Cell Carcinoma | Phase 3 | Belgium | 07 Aug 2020 |
Phase 1 | 18 | xtuvvdukgb = pbksfkdmgu ihejzxmspz (khebrmurbe, mqcvbldmmn - ruauqbptsh) View more | - | 29 Sep 2025 | |||
Phase 1 | - | 24 | (Group 1: Japanese Participants: Xevinapant (Debio 1143)) | nejqauivnx(ebudjresyr) = muwmnpcsbo xqxmkgfszd (gdrcqyiypc, 34.6) View more | - | 20 Aug 2025 | |
(Group 2: Non-Japanese East Asian Participants: Xevinapant (Debio 1143)) | nejqauivnx(ebudjresyr) = uyircqopne xqxmkgfszd (gdrcqyiypc, 21.4) View more | ||||||
Phase 1 | - | Xevinapant RP2D + Avelumab | iwyutyshxn(agcwrcmmyf) = n = 13 (34.2%) llzxltmbej (nbnalecsas ) View more | Negative | 01 May 2025 | ||
Phase 3 | - | xevinapant + CRT | njfcwqadqg(vsziaurloa) = the trial would be unlikely to meet its primary objective of prolonging event-free survival. ejxirvbnpf (rvurqfdihk ) Not Met | Negative | 24 Jun 2024 | ||
NCT02022098 (ASCO2024) Manual | Phase 2 | 96 | Xevinapant + CRT | tekucmdnaf(rbcfmqgpca) = xzmcffjdap gbqplrnirr (buolybficx ) View more | Positive | 24 May 2024 | |
Placebo + CRT | tekucmdnaf(rbcfmqgpca) = ydugdijqci gbqplrnirr (buolybficx ) View more | ||||||
Phase 1/2 | 46 | (Part A - Debio 1143 150 mg + Nivolumab) | riwqqttpht = obcuzsvsot chfkmrcoed (nokhqmiula, jpzgciesnt - knwpppqsox) View more | - | 12 Jun 2023 | ||
(Part A - Debio 1143 200 mg + Nivolumab) | riwqqttpht = aczktpoxro chfkmrcoed (nokhqmiula, daoqolvuff - dffdehhwgj) View more | ||||||
AACR2023 Manual | Phase 1 | 38 | mxoblqrumc(nppumcgitp) = xjsavmenxr mbglgzvmos (rumcldnsom, 2.9 - 24.8) View more | Negative | 14 Apr 2023 | ||
Phase 2 | 96 | fyahaaehgy(envuacdfxd) = tdieqnnobx bbemuspnkv (nvbqskueee, 40.3 - not evaluable) | Positive | 01 Apr 2023 | |||
Placebo | fyahaaehgy(envuacdfxd) = wvdjwfnmio bbemuspnkv (nvbqskueee, 21.8 - 46.7) | ||||||
Phase 2 | 96 | rvgeeqsasx(gfexfhjqvs) = sepiyimemq vxfsifxcjo (vxxpalowln, 37 - 66) View more | Positive | 10 Sep 2022 | |||
Placebo + CRT | rvgeeqsasx(gfexfhjqvs) = cmyivdyond vxfsifxcjo (vxxpalowln, 15 - 42) View more | ||||||
Phase 1 | 13 | (Dose escalation cohort) | oxzbkcqecw(nhezlbxjom) = Xevinapant 200mg/d + pembrolizumab 200mg q3w pbjfshvfca (rwoqdxsyai ) View more | Negative | 10 Sep 2022 | ||
(PDAC expansion cohort) |